Private Advisor Group LLC Purchases 12,000 Shares of Exscientia plc (NASDAQ:EXAI)

Private Advisor Group LLC raised its position in Exscientia plc (NASDAQ:EXAIFree Report) by 114.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,500 shares of the company’s stock after buying an additional 12,000 shares during the quarter. Private Advisor Group LLC’s holdings in Exscientia were worth $144,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Banque Pictet & Cie SA bought a new position in Exscientia in the 3rd quarter worth approximately $1,040,000. Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Exscientia by 6.0% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 203,970 shares of the company’s stock worth $922,000 after acquiring an additional 11,570 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Exscientia by 26.4% in the third quarter. Bank of New York Mellon Corp now owns 155,097 shares of the company’s stock worth $701,000 after acquiring an additional 32,373 shares during the period. Federated Hermes Inc. purchased a new position in shares of Exscientia in the third quarter valued at $362,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Exscientia during the 3rd quarter valued at $344,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Analysts Set New Price Targets

Separately, Morgan Stanley reaffirmed an “equal weight” rating and set a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd.

Get Our Latest Stock Report on EXAI

Exscientia Trading Down 0.8 %

Exscientia stock opened at $4.69 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.30. Exscientia plc has a fifty-two week low of $3.86 and a fifty-two week high of $9.12. The stock has a market cap of $566.96 million, a P/E ratio of -3.58 and a beta of 0.82. The firm’s fifty day moving average price is $5.01 and its 200-day moving average price is $5.76.

Exscientia (NASDAQ:EXAIGet Free Report) last announced its earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Exscientia had a negative return on equity of 34.59% and a negative net margin of 666.80%. The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $41.63 million. Equities research analysts forecast that Exscientia plc will post -1.07 earnings per share for the current fiscal year.

Exscientia Profile

(Free Report)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

Read More

Want to see what other hedge funds are holding EXAI? Visit to get the latest 13F filings and insider trades for Exscientia plc (NASDAQ:EXAIFree Report).

Institutional Ownership by Quarter for Exscientia (NASDAQ:EXAI)

Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with's FREE daily email newsletter.